Drug intelligence / Profile preview

CTL0902

Development stage: Unknown
Lead developer: Celltrion
Modality: Small Molecules
Administration: Oral

Overview

CTL0902 is an investigational drug currently being evaluated in a phase 1 clinical trial for its pharmacokinetic interaction and safety profile when administered alone and in combination with another investigational agent, CTL0901, in healthy adult volunteers. It is being studied through repeated oral dosing. Detailed information regarding the mechanism of action, therapeutic indication, and molecular modality is not available in public sources or the cited clinical trial documentation[1].

Brand names: CTL0902CTL-0902CTL 0902
Other names: CTL0902CTL-0902CTL 0902

Targets

NPC1L1 (Niemann-pick C1-Like 1 transporter)

Beyond the preview

Go deeper on CTL0902.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CTL0902.

Explore the full profile